Immunogenomics Market (2026-2036)

The growth of this market is mainly driven by the rapid adoption of immunosequencing-based minimal residual disease testing in hematologic malignancies, the transition of HLA typing from serological and PCR-based methods to high-resolution next-generation sequencing (NGS) and long-read sequencing, the growth of immuno-oncology and cell therapy development, and the increasing use of immune repertoire and single-cell immune profiling in research. In addition, the expansion of solid organ and stem cell transplantation, the growing application of immunogenomics in autoimmune and infectious diseases, the development of neoantigen-based personalized cancer vaccines, and the use of artificial intelligence (AI) to interpret immune receptor data are further supporting the growth of this market.

The Immunogenomics Market, also referred to as the immune genomics market, immune repertoire and HLA genomics market, or immunogenetics sequencing market, comprises the kits and reagents, instruments, software, and services used to analyze the genes and genetic diversity of the immune system. The market includes immune repertoire sequencing of T-cell receptors (TCRs) and B-cell receptors (BCRs), including clinical immunosequencing for MRD detection; HLA and killer-cell immunoglobulin-like receptor (KIR) typing using NGS, long-read sequencing, and PCR-based methods; immune gene expression profiling; single-cell immune profiling that links immune receptor sequences to gene expression; neoantigen prediction and immunopeptidome analysis; and the bioinformatics tools used to interpret immune genomic data. The market ecosystem extends from sequencing platform and reagent providers to HLA typing kit manufacturers, clinical immunosequencing laboratories, bioinformatics providers, transplant and histocompatibility laboratories, donor registries, academic research institutions, and pharmaceutical and biotechnology companies.

The market is experiencing strong growth as the immune system becomes central to the diagnosis and treatment of many diseases. The diversity of immune receptors and HLA genes determines how individuals respond to infections, cancers, transplants, and vaccines, and sequencing technologies now allow this diversity to be measured comprehensively. In oncology, immune repertoire sequencing allows clonal B-cell and T-cell populations to be tracked with very high sensitivity, enabling the detection of MRD in blood cancers. In transplantation, high-resolution HLA typing improves donor-recipient matching and outcomes. In research and drug development, immunogenomic data are used to understand immune responses, discover therapeutic antibodies and TCRs, and design immunotherapies and vaccines.

Clinical immunosequencing is one of the most important growth drivers. Adaptive Biotechnologies reported Q2 2026 minimal residual disease (MRD) revenue of USD 66.2 million, up 33%, with clonoSEQ test volume rising 43% to 36,111 tests, raised its 2026 MRD revenue guidance to USD 268 million to USD 278 million, and announced plans to separate its MRD and Immune Medicine businesses. The clonoSEQ assay identifies and tracks the clonal immune receptor sequences of malignant cells in multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and lymphomas, and MRD status is increasingly used to guide treatment decisions and as an endpoint in clinical trials. The strong growth of MRD testing illustrates how immunogenomics is moving from research into routine clinical practice.

HLA typing is also evolving rapidly. Histocompatibility laboratories have moved from serological and low-resolution PCR methods toward high-resolution NGS-based typing, which provides more accurate matching for solid organ and hematopoietic stem cell transplantation. In March 2025, Thermo Fisher Scientific introduced the One Lambda HybriType HLA Plus Typing Flex kit, an NGS hybrid capture assay for HLA genotyping from whole blood and buccal swabs with at least 99.8% concordance and a total workflow time of under 5.5 hours, supported by One Lambda TypeStream Visual NGS Software. In April 2026, CareDx introduced AlloSeq Nano at the European Federation for Immunogenetics (EFI) conference, a nanopore-based long-read HLA typing assay that genotypes eleven HLA loci plus ABO in a single assay in under three hours, with about 45 minutes of hands-on time and reduced phasing ambiguities. Long-read sequencing reduces phasing ambiguities in highly polymorphic HLA genes, supporting more accurate and faster typing, particularly for deceased donor typing where speed is critical.

The competitive landscape is consolidating as companies focus their portfolios. In April 2026, CareDx agreed to divest its Lab Products business, including NGS-based and PCR-based HLA typing kits and the newly introduced AlloSeq Nano long-read HLA typing assay, to Eurobio Scientific for USD 170 million in cash, with closing expected by the end of the third quarter of 2026. Adaptive Biotechnologies has announced plans to separate its MRD and Immune Medicine businesses, and Thermo Fisher Scientific offers a broad transplant diagnostics portfolio through One Lambda. In research, single-cell platforms such as those of 10x Genomics enable paired immune receptor and gene expression analysis, while companies such as Takara Bio and Invivoscribe offer immune repertoire library preparation and clonality assays.

Immunogenomics is also expanding into new applications. In autoimmune diseases, immune repertoire sequencing is being used to identify disease-associated T-cell and B-cell clones and to monitor immune responses to therapies, including emerging cell therapies for autoimmune conditions. In infectious diseases, immune repertoire data can reveal past and current exposures and vaccine responses. In immuno-oncology, neoantigen prediction from tumor sequencing supports the development of personalized cancer vaccines, and TCR sequencing is used to monitor responses to checkpoint inhibitors and cell therapies.

At the same time, the market faces challenges related to the complexity of immune genomic data, the cost of high-resolution analysis, and reimbursement and regulatory requirements for clinical tests. Adaptive Biotechnologies reported a decline in Immune Medicine revenue to USD 5.4 million in Q2 2026, reflecting the difficulty of commercializing immune repertoire data for drug discovery outside clinical MRD testing. As a result, providers that can deliver clinically validated tests, rapid and accurate HLA typing, and interpretable immune profiling are expected to capture the largest share of growth over the forecast period.